As of June 30, 2025, Xilio had cash and cash equivalents of $121.6M. Based on its current operating plans, Xilio anticipates that its cash and cash equivalents as of June 30, 2025, together with the $17.5M development milestone achieved under the license agreement with Gilead, will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the first quarter of 2027. Xilio expects to receive payment of the $17.5M development milestone by the fourth quarter of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XLO:
- Xilio Therapeutics Faces Nasdaq Equity Compliance Challenge
- Xilio Therapeutics Reports Strong Pipeline Progress and Financial Results
- Promising Future for Xilio Therapeutics: Strong Financial Position and Encouraging Trial Results Support Buy Rating
- Xilio Therapeutics reports Q2 EPS (16c) vs (24c) last year
- Snap downgraded, Leidos upgraded: Wall Street’s top analyst calls